Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study

Journal of Bone and Mineral Research

Volumn 20, Issue 1, 2005, Pages 141-151

  Rosen, Clifford J ^a   Hochberg, Marc C ^b   Bonnick, Sydney L ^c   McClung, Michael ^d   Miller, Paul ^e   Broy, Susan ^f   Kagan, Risa ^g   Chen, Erluo ^h   Petruschke, Richard A ^h   Thompson, Desmond E ^h   De Papp, Anne E ^h  

^a ST JOSEPH HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Clinical Research Center of North Texas   (United States)

^d OREGON OSTEOPOROSIS CENTER   (United States)

^e University of Colorado Health Sciences Center   (United States)

^f ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^g Foundation for Osteoporosis Research and Education   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Biochemical markers; BMD; Risedronate; Tolerability

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; RISEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FEMUR NECK; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; BONE REMODELING; COMPARATIVE STUDY; MIDDLE AGED; UNITED STATES;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM CHANNEL BLOCKERS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; UNITED STATES;

EID: 14644407147     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2005.20.1.141     Document Type: Article

References (49)

1. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases. NIH Consensus Statement-Osteoporosis Prevention, Diagnosis, and Therapy. Available online at http://consensus.nih. gov/cons/111/ 111_statement.htm. Accessed April 20, 2004.
2. National Osteoporosis Foundation (NOF) Physician's Guide to Prevention and Treatment of Osteoporosis. Available online at http://www.nof.org// physguide/risk_assessment.htm. Accessed April 20, 2004.
3. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. The study of Osteoporotic Fractures Research Group. Lancet 341:72-75.
4. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W 1992 Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 7:633-638.
5. Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD 1998 Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563-569.
6. Hannon RA, Eastell R 2003 Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 9:10-15.
7. Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, Richy F, Reginster JY 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44:259-265.
8. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
9. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner MCT, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with Osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
10. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
11. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal Osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
12. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254.
13. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
14. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401.
15. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
16. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258.
17. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
18. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
19. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
20. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188.
21. Marcus R, Wong M, Heath H III, Stock JL 2002 Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37.
22. Delmas PD, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604.
23. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12.
24. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111.
25. McAlister FA, Laupacis A, Wells GA, Sackett DL 1999 Users' Guides to the Medical Literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282:1371-1377.
26. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA 1999 Users' Guides to the Medical Literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints. Evidence-based medicine working group. JAMA 282:771-778.
27. Hosking D, Adami S, Felsenberg D, Cannata Andia J, Valimaki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC 2003 Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomized placebo-controlled study. Curr Med Res Opin 19:383-394.
28. Anonymous 2002 Fosamax (alendronate sodium) prescribing information. In: Physicians' Desk Reference, 56th ed. Medical Economics Co., Montvale, NJ, USA, pp. 2095-2102.
29. Anonymous 2002 Actonel (risedronate sodium) prescribing information. In: Physicians' Desk Reference, 56th ed. Medical Economics Co., Montvale, NJ, USA, pp 2879-2884.
30. Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD 2003 Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study. J Bone Miner Res 18:1789-1794.
31. Sankoh AJ, Huque MF, Dubey SD 1997 Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16:2529-2542.
32. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516.
33. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523.
34. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-577.
35. Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC 1997 Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7:564-569.
36. Bonnick SL, Lewis LA 2002 The precision of PA spine, Dual-Femur® and single femur bone density studies on the GE Lunar Prodigy, a DXA fan-array device. J Clin Densitom 5:S48.
37. Nevitt MC, Lane NE, Scott JC, Hochberg MC, Pressman AR, Genant HK, Cummings SR 1995 Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. Arthritis Rheum 38:907-916.
38. Bonnick SL, Johnston CC, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E 2001 Importance of precision in bone density measurements. J Clin Densitom 4:105-110.
39. Chesnut CH III, Rosen CJ for The Bone Quality Discussion Group 2001 Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172.
40. Parfitt AM 1993 Pathophysiology of bone fragility. In: Christiansen C, Riis BJ (eds.) Osteoporosis. Osteopress, Copenhagen, The Netherlands, pp. 164-166.
41. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538.
42. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349.
43. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930.
44. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biochemical properties in dog rib. J Bone Miner Res 15:613-620.
45. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199.
46. Sorensen O, Goemare S, Wenderoth D, Chines A, Roux C 2003 Sustained effect of risedronate: A 7-year study in postmenopausal women. Calcif Tissue Int 72:402.
47. Delmas PD, Li Z, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337.
48. Freedman DA, Klein SP, Ostland M, Roberts MR 1998 Review of a solution to the ecological inference problem. J Am Stat Assoc 93:1518-1522.
49. Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandra JM, Abadie E, Lekkerkerker F 2002 Uncertain future of trials in osteoporosis. Osteoporos Int 13:443-449.